Haohua Zhu

机构：Nanchang University, Chinese Academy of Medical Sciences & Peking Union Medical College, Third Affiliated Hospital of Nanchang University, First Affiliated Hospital of Nanchang University · ORCID：0000-0002-7914-0289

发表论文 36 篇 · 总被引 171 次 · h-index 8

代表论文

• Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000–2025) (2025 · Journal of Hematology & Oncology · 被引 27)
• Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer (2023 · BMC Cancer · 被引 16)
• A 16-year evaluation of opportunistic lung cancer screening with low-dose CT in China: comparative findings between non-smokers and smokers (2024 · BMC Cancer · 被引 11)
• Multi-omics analysis and response prediction of PD-1 monoclonal antibody containing regimens in patients with relapsed/refractory diffuse large B-cell lymphoma (2024 · Cancer Immunology Immunotherapy · 被引 8)
• DLX2 Is a Potential Immune-Related Prognostic Indicator Associated with Remodeling of Tumor Microenvironment in Lung Squamous Cell Carcinoma: An Integrated Bioinformatical Analysis (2022 · Disease Markers · 被引 7)
• Efficacy, safety, and multi-omics analysis of pembrolizumab combined with nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: A single-arm phase 2 study (2024 · Chinese Journal of Cancer Research · 被引 5)